- Home
- FSHP vs MAIA Comparison
FSHP vs MAIA Comparison
Compare FSHP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- MAIA
- Stock Information
- Founded
- FSHP 2018
- MAIA 2018
- Country
- FSHP United States
- MAIA United States
- Employees
- FSHP N/A
- MAIA N/A
- Industry
- FSHP
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FSHP
- MAIA Health Care
- Exchange
- FSHP NYSE
- MAIA Nasdaq
- Market Cap
- FSHP 88.7M
- MAIA 72.7M
- IPO Year
- FSHP 2024
- MAIA 2022
- Fundamental
- Price
- FSHP $10.02
- MAIA $2.81
- Analyst Decision
- FSHP
- MAIA
- Analyst Count
- FSHP 0
- MAIA 0
- Target Price
- FSHP N/A
- MAIA N/A
- AVG Volume (30 Days)
- FSHP 19.9K
- MAIA 138.2K
- Earning Date
- FSHP 01-01-0001
- MAIA 11-05-2024
- Dividend Yield
- FSHP N/A
- MAIA N/A
- EPS Growth
- FSHP N/A
- MAIA N/A
- EPS
- FSHP N/A
- MAIA N/A
- Revenue
- FSHP N/A
- MAIA N/A
- Revenue This Year
- FSHP N/A
- MAIA N/A
- Revenue Next Year
- FSHP N/A
- MAIA N/A
- P/E Ratio
- FSHP N/A
- MAIA N/A
- Revenue Growth
- FSHP N/A
- MAIA N/A
- 52 Week Low
- FSHP $9.99
- MAIA $0.82
- 52 Week High
- FSHP $10.03
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- MAIA 43.25
- Support Level
- FSHP N/A
- MAIA $2.85
- Resistance Level
- FSHP N/A
- MAIA $3.62
- Average True Range (ATR)
- FSHP 0.00
- MAIA 0.35
- MACD
- FSHP 0.00
- MAIA -0.02
- Stochastic Oscillator
- FSHP 0.00
- MAIA 13.06
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.